Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASAZontag and Zontag used a retrospective cohort design to evaluate the risk of smell and taste disturbances in patients being treated with glucagon-like peptide-1 agonists (GLP-1 RA). They used health records from a large electronic health records database (TriNetX Global Collaborative Network) encompassing more than 120 health care organizations to query adults with type 2 diabetes (T2D) without preexisting smell or taste disturbances. The exposure cohort received a GLP-1 RA while the control cohort was prescribed T2D medications without a GLP-1 RA. Each cohort had more than 400 000 patients. The authors found that the GLP-1 RA cohort had an increased risk of overall taste and disturbances (hazard ratio, 1.48; 95% CI, 1.37-1.61). The authors suggest that GLP-1 RA therapy is associated with a higher risk of smell and taste disturbance and raise a call for public health awareness.